The feasibility and potential of pharmacogenetics to reduce adverse drug events in nursing home residents
Christine E. Kistler,Charles Adrian Austin,Junjian J. Liu,Madison Cauble,Andrew Wise,Sheel M. Patel,Kimberly Ward,Tim Wiltshire,Fei Zou,Andy H. Szeto,Daniel J. Crona
DOI: https://doi.org/10.1111/jgs.17679
2022-02-14
Journal of the American Geriatrics Society
Abstract:TABLE 1. Potentially inappropriate medications based on "at-risk" drug-genotype pairsGene nameAt-risk drug (n)Guidance to cliniciansCYP1A2Moderate: Lidocaineaa Denotes guidance only applicable to systemic (non-dermal) dosage forms, and "n" in the at-risk drug column indicates the number of participants with the drug-genotype pair. , Mirtazapine (1)Lower starting doses may be effective. Monitor for adverse events at standard doses and consider TDM if available.CYP2C19Major: Clopidogrel (1)Moderate: Citalopram (1), Omeprazole (2)Major: Consider initiating another medication (e.g., prasugrel or ticagrelor).Moderate: For citalopram, initiate a normal dose and monitor closely for slower than expected efficacy.For omeprazole, initiate the normal dose, but should consider higher starting doses if using for H. pylori eradication.CYP2C9Moderate: Celecoxib (1)Glipizide (2)Lower starting doses may be effective. Monitor for adverse events at standard doses and consider TDM if available.CYP2D6Major: Carvedilol (1), Fluoxetine (1), Hydrocodone (2), Metoprolol (1), Ondansetron (1), Oxycodone (2), Tamsulosin (1), Tramadol (1)Moderate: Donepezil (1), Hydrocodone (1), Metoprolol (1), Mirtazapine (1), Ondansetron (4), Oxycodone (1), Propranolol (1), Tamsulosin (1), Tramadol (1)Major: For carvedilol, initiate at normal doses, but monitor closely for dizziness and falls. Do not switch to metoprolol or timolol.For fluoxetine, lower starting doses may be effective.For hydrocodone, oxycodone, and tramadol, consider an alternate non-CYP2D6 substrate analgesic; altered metabolism can lead to ineffective analgesia and increased toxicities.For metoprolol, when patients have increased CNV and ultrarapid metabolism, can consider titrating up to 2.5 times the approved dose. Consider alternative non-CYP2D6 substrate medications (e.g., bisoprolol or atenolol).For ondansetron, when patients have increased CNV and ultrarapid metabolism, consider alternative non-CYP2D6 substrate medications (e.g., granisetron).For tamsulosin, when patients are poor metabolizers, do not use the 0.8 mg dose, and use caution with the 0.4 mg dose.Moderate: For oxycodone and tramadol, initiate a normal dose when intermediate metabolizers, but monitor closely for toxicities.For other medications, lower starting doses may be effective. Monitor for adverse events at standard doses and consider TDM if available.CYP3A4/5Moderate: Atorvastatin (1), Diltizazem (1), Hydrocodone (1), Oxybutinin (1), Oxycodone (1)Lower starting doses may be effective. Monitor for adverse events at standard doses and consider TDM if available.For hydrocodone and oxycodone, consider an alternate non-CYP2D6 substrate analgesic; altered metabolism can lead to ineffective analgesia and increased toxicities. If switching to an alternative, do not use hydrocodone, oxycodone, or tramadol.OPRM1 ; Asn > Asp (rs1799971 118A > G)Moderate: Tramadol (1)Initiate tramadol at normal doses. However, altered metabolism could require h -Abstract Truncated-
geriatrics & gerontology,gerontology